November 01, 2022

Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

November 01, 2022

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

October 19, 2022

Sobera Capital exits TM3 Software to proLogistik

May 31, 2022

Memo Therapeutics AG initiates phase 1 clinical study of MTX-005 against BK virus infection

May 24, 2022

ERS electronic introduces ProbeSense™, a state-of-the-art measurement device for automated temperature calibration in wafer test

February 16, 2022

Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension

January 14, 2022

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

January 03, 2022

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402